2.22
+0.009(+0.41%)
Currency In USD
| Previous Close | 2.21 |
| Open | 2.17 |
| Day High | 2.39 |
| Day Low | 2.09 |
| 52-Week High | 6.9 |
| 52-Week Low | 1.69 |
| Volume | 234,229 |
| Average Volume | 93,144 |
| Market Cap | 5.73M |
| PE | -0.78 |
| EPS | -2.84 |
| Moving Average 50 Days | 3.3 |
| Moving Average 200 Days | 2.97 |
| Change | 0.01 |
If you invested $1000 in Creative Medical Technology Holdings, Inc. (CELZ) 10 years ago, it would be worth $0.27 as of December 04, 2025 at a share price of $2.22. Whereas If you bought $1000 worth of Creative Medical Technology Holdings, Inc. (CELZ) shares 5 years ago, it would be worth $246.67 as of December 04, 2025 at a share price of $2.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
GlobeNewswire Inc.
Dec 02, 2025 2:15 PM GMT
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global marketsPHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Techno
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
GlobeNewswire Inc.
Oct 30, 2025 1:15 PM GMT
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine PlatformPHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage lead
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
GlobeNewswire Inc.
Oct 29, 2025 1:00 PM GMT
PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements